Network Pharmacology Integrated with Transcriptomics Analysis Reveals Ermiao Wan Alleviates Atopic Dermatitis via Suppressing MAPK and Activating the EGFR/AKT Signaling
Ting Xia,Xiao Liang,Chang-Shun Liu,Yan-Nan Hu,Zhen-Ye Luo,Xiao-Mei Tan
DOI: https://doi.org/10.2147/DDDT.S384927
2022-12-21
Abstract:Ting Xia, 1– 3 Xiao Liang, 4 Chang-Shun Liu, 1– 3 Yan-Nan Hu, 1– 3 Zhen-Ye Luo, 1– 3 Xiao-Mei Tan 1– 3 1 School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, People's Republic of China; 2 Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, Southern Medical University, Guangzhou, 510515, People's Republic of China; 3 Guangdong Provincial Engineering Laboratory of Chinese Medicine Preparation Technology, Guangzhou, 510515, People's Republic of China; 4 School of Pharmaceutical Sciences, Guilin Medical University, Guilin, 541199, People's Republic of China Correspondence: Xiao-Mei Tan, Tel/Fax + 86-020-61648265, Email Background: Ermiao Wan (EMW) is commonly used to treat atopic dermatitis (AD) in China. However, the pharmacological mechanisms underlying the action of EMW against AD remain unclear. Purpose: We aimed to determine the mechanisms underlying the effectiveness of EMW in the treatment of AD. Methods: We evaluated the effect of EMW on AD induced by dinitrochlorobenzene (DNCB) in BALB/C mice. To clarify the key components of EMW in AD treatment, the main components of EMW were identified using HPLC. Serum pharmacochemistry was used to analyze the absorbed ingredients from blood. Based on the phytochemical results, network pharmacology and molecular docking were used to predict the action of EMW. Skin transcriptomic analysis was used to validate the network pharmacology results. RT-qPCR,ELISA, and immunohistochemical were performed to validate the results of skin transcriptomics. Results: EMW improved the symptoms of AD, with less rashes, less spontaneous scratching, less inflammatory cell infiltration, and fewer allergic reactions. The established HPLC method is simple and reliable. Chlorogenic acid, phellodendrine, magnoflorine, jatrorrhizine, palmatine, berberine, and atractylodin were the key effective ingredients with a high blood concentration. Fifty-seven primary causal targets of EMW against AD were identified. These targets are mainly involved in ErbB signaling pathways including EGFR, AKT1, MAPK8, JUN, MAPK1. Molecular docking showed that EGFR, AKT1, MAPK8, JUN, MAPK1 had good binding force with EMW. In AD mice, EMW regulated the EGFR/AKT signaling through upregulation of Grb2, GAB1, Raf-1, EGFR, and AKT, and downregulation of MAPK1 and JUN, compared to that in the MD group. Conclusion: EMW could alleviate AD through activating EGFR/AKT signaling and suppressing MAPK. This study provides a theoretical basis for the clinical use of EMW. Keywords: Ermiao Wan, atopic dermatitis, network pharmacology, serum pharmacochemistry, skin transcriptome, EGFR/AKT signaling Atopic dermatitis (AD) is a common chronic, inflammatory skin disorder characterized by severe pruritus, with a complex pathogenesis and recurrent attacks. 1 It seriously reduces work enthusiasm and life quality, especially in those with moderate to severe AD. Approximately 200 million people worldwide are affected by AD. 2 In addition, with the outbreak of COVID-19, 97.0% of health care workers had skin damage and AD because of enhanced infection-prevention measures. 3,4 Antibiotics are commonly used to relieve AD symptoms. However, there are adverse reactions such as drug resistance, hormone-dependent dermatitis, skin atrophy. 5 Traditional Chinese medicine (TCM) has the advantages of good therapeutic effect, high safety, and less side effects. Ermiao Wan (EMW) is commonly used in the clinical treatment of AD in China. The clinical application of EMW for preventing AD first appeared in the book of Danxi Xinfa, which is from the Ming Dynasty. EMW is used to relieve the symptoms of AD, such as rash and spontaneous scratching. 6 EMW is composed of Atractylodis Rhizoma (AR) and Phellodendri Cortex (PC) in a 1:1 ratio. PC alleviates the symptoms of specific dermatitis by reducing the phosphorylation of MAPKs, inhibiting the activity of NF-κB, and suppressing M1 polarization of macrophages. 6,7 In addition, the volatile components in AR prevent AD. 8 The alkaloids in EMW have good biological activity, 9,10 which can improve skin pruritus by inhibiting serum Th1/2 cytokines, and suppressing the phosphorylation of JNK, ERK and P38 in the skin. 11 Owing to the multi-component and multi-target characteristics, the mechanisms underlying the therapeutic effects of EMW in AD are unclear. It is difficult to clarify the mechanism of EMW in treating AD using conventional methods. Network pharmacology is a novel discipline that integrates biology, pharmacology, and informatics. 12</s -Abstract Truncated-